Stock Price Quote

PANACEA BIOTEC LTD.

NSE : PANACEABIOBSE : 531349ISIN CODE : INE922B01023Industry : Pharmaceuticals & DrugsHouse : Soshil Kumar Jain
BSE136.00-1.35 (-0.98 %)
PREV CLOSE ( ) 137.35
OPEN PRICE ( ) 137.25
BID PRICE (QTY) 135.25 (4)
OFFER PRICE (QTY) 135.90 (4)
VOLUME 1266
TODAY'S LOW / HIGH ( )134.70 137.25
52 WK LOW / HIGH ( )113.55 202.2
NSE136.00-1.45 (-1.05 %)
PREV CLOSE( ) 137.45
OPEN PRICE ( ) 135.80
BID PRICE (QTY) 136.15 (24)
OFFER PRICE (QTY) 136.45 (26)
VOLUME 23492
TODAY'S LOW / HIGH( ) 134.70 137.00
52 WK LOW / HIGH ( )114.2 202.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Rajesh Jain - Chairman Rajesh Jain - Managing Director
Registered Office

Address Ambala - Chandigarh Highway,,,
Lalru,
Punjab-140501

Phone 01762- 505900

Email companysec@panaceabiotec.com

Website www.panaceabiotec.com

Registrars Details
Skyline Financial Services Pvt Ltd
D-153/A, 1st Floor,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE, MCX

NEWS

05Apr Panacea Biotec informs about details o
With reference to CDSL’s Operating Instructions for Issuers/RTAs which s..
13Mar Panacea Biotec informs about newspaper
In continuation to letter dated March 12, 2024 and pursuant to Regulatio..
12Mar Panacea Biotec informs about notice of
Panacea Biotec has informed that it enclosed Postal Ballot Notice - Disc..
30Jan Panacea Biotec informs about board mee
Panacea Biotec has informed that meeting of the Board of Directors of th..
15Dec Panacea Biotec shines on launching ful
Panacea Biotec is currently trading at Rs. 170.40, up by 7.40 points or..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit4.29999999999997-875.4
Gross Profit 10.7 -627.5
Operating Profit 96.9-281.9
Net Sales 952.32570.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Mercury Laboratories (BSE)
peergroup  924.00 (3.81%)
M.Cap ( in Cr)106.81
Sanjivani Paranteral (BSE)
peergroup  181.00 (7.35%)
M.Cap ( in Cr)197.00
Chandra Bhagat Pharm (BSE)
peergroup  113.85 (11.60%)
M.Cap ( in Cr)76.97
TTK Healthcare (BSE)
peergroup  1537.50 (0.55%)
M.Cap ( in Cr)2160.60
Aarti Pharmalabs (BSE)
peergroup  503.70 (1.27%)
M.Cap ( in Cr)4507.74

Shareholding Pattern

PROMOTERS 73.59%
NON-INSTITUTION 25.3%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Panacea Biotec Ltd.

Panacea Biotec Ltd. was incorporated in the year 1984. Its today's share price is 136. Its current market capitalisation stands at Rs 841.28 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2587.28 Cr and Total Income of Rs.2915.02 Cr. The company's management includes Narotam Kumar Juneja, Mukul Gupta, Manjula Upadhyay, Bhupinder Singh, Ankesh Jain, Sandeep Jain, Rajesh Jain, Rajesh Jain, Vinod Goel.

It is listed on the BSE with a BSE Code of 531349 , NSE with an NSE Symbol of PANACEABIO and ISIN of INE922B01023. It's Registered office is at Ambala - Chandigarh Highway,,Lalru-140501, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are SR Batliboi & Co LLP, Walker Chandiok & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.